Endymed Third Quarter 2023 Earnings: US$0.032 loss per share (vs US$0.016 loss in 3Q 2022)

Endymed (TLV:ENDY) Third Quarter 2023 Results

Key Financial Results

• Revenue: US$5.10m (up 21% from 3Q 2022).
• Net loss: US$445.0k (loss widened by 102% from 3Q 2022).
• US$0.032 loss per share (further deteriorated from US$0.016 loss in 3Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Endymed shares are down 10% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Endymed (1 is a bit concerning!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.